Carmel Capital Partners’s Biogen BIIB Stock Holding History

Carmel Capital Partners’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-7	Closed	-$1.99K	–	760
2023 Q2	$1.99K	Hold	7	–	–	﹤0.01%	365
2023 Q1	$1.95K	Buy	+7	New	+$1.94K	﹤0.01%	408

Other funds holding BIIB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Carmel Capital Partners's BIIB Position: Q3 2023 in Review

Carmel Capital Partners sold out of Biogen (BIIB) in Q3 2023, closing a stake of 7 shares — an estimated $1.99K sold.

Carmel Capital Partners first reported a position in BIIB in Q1 2023 and held it in 2 quarters. The position peaked at $1.99K in Q2 2023. 965 funds tracked by Wall St. Rank hold BIIB as of Q3 2023.

Carmel Capital Partners reported no remaining Biogen position as of Q3 2023 after selling out during the quarter.
Carmel Capital Partners sold 7 Biogen shares in Q3 2023, an estimated $1.99K.
Carmel Capital Partners first reported a position in Biogen in Q1 2023 and held it in 2 quarters.
Carmel Capital Partners's Biogen position peaked at $1.99K in Q2 2023.
965 funds tracked by Wall St. Rank held Biogen as of Q3 2023.

Based on Carmel Capital Partners's 13F filing for Q3 2023, filed 27 Oct 2023.